Peter J M Valk
Overview
Explore the profile of Peter J M Valk including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
175
Citations
10190
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pavlova S, Malcikova J, Radova L, Bonfiglio S, Cowland J, Brieghel C, et al.
Hemasphere
. 2025 Jan;
9(1):e70065.
PMID: 39840379
In chronic lymphocytic leukemia, the reliability of next-generation sequencing (NGS) to detect variants ≤10% allelic frequency (low-VAF) is debated. We tested the ability to detect 23 such variants in 41...
2.
Ernst M, Versluis J, Valk P, Bierings M, Tamminga R, Hooimeijer L, et al.
Hemasphere
. 2025 Jan;
9(1):e70057.
PMID: 39822584
Familial Platelet Disorder with associated Myeloid Malignancy (FPDMM, FPD/AML, -FPD), caused by monoallelic deleterious germline variants, is characterized by bleeding diathesis and predisposition for hematologic malignancies, particularly myelodysplastic syndrome (MDS)...
3.
Boertjes E, Massaar S, Zeilemaker A, Konijnenburg J, Rijken M, Kavelaars F, et al.
Blood Adv
. 2024 Dec;
9(6):1344-1355.
PMID: 39693514
Mutation of DNMT3A, encoding a de novo methyltransferase essential for cytosine methylation, is a common early event in clonal hematopoiesis (CH) and adult acute myeloid leukemia (AML). Spontaneous deamination of...
4.
Vonk C, Grob T, Rijken M, Kavelaars F, Konijnenburg J, Konijnenburg J, et al.
Blood Adv
. 2024 Dec;
9(5):1069-1077.
PMID: 39637308
Mutations in the nucleophosmin-1 (NPM1) gene are among the most common molecular aberrations in acute myeloid leukemia (AML). Various studies have established mutant NPM1 (mNPM1) as a faithful molecular measurable...
5.
Arza-Apalategi S, Heuts B, Bergevoet S, Meering R, Gilissen D, Jansen P, et al.
Leukemia
. 2024 Dec;
39(2):371-380.
PMID: 39633068
KMT2A::MLLT3 acute myelomonocytic leukemia (AML) comes in two clinically and biologically different subtypes. One is characterized by inferior outcome, older age, and MECOM oncogene expression. The other is mainly observed...
6.
Bajrami Saipi M, Ruiba A, Schittenhelm M, Blumenstock G, Gyorffy B, Fazio S, et al.
Cell Death Dis
. 2024 Nov;
15(11):869.
PMID: 39616159
Apoptosis-stimulating proteins of p53 (ASPPs) are a family of proteins that modulate key tumor suppressor pathways via direct interaction with p53. Deregulation of these proteins promotes cancer development and impairs...
7.
Kockerols C, Valk P, Hogenbirk P, Cornelissen J, Westerweel P
J Mol Diagn
. 2024 Nov;
27(2):109-118.
PMID: 39615652
BCR::ABL1 digital PCR is a promising technique for the quantification of deep molecular responses (DMRs) in chronic myeloid leukemia. It provides an improved precision and sensitivity compared with conventional real-time...
8.
Silva W, Kim H, Undurraga M, Navarro-Cabrera J, Salinas V, Muxi P, et al.
Haematologica
. 2024 Oct;
110(3):795-798.
PMID: 39479861
No abstract available.
9.
Huls G, Chitu D, Tick L, Boersma R, Breems D, Herbers A, et al.
Ann Hematol
. 2024 Oct;
104(1):361-368.
PMID: 39367118
The treatment of older patients with acute myeloid leukemia (AML) considered unfit for receiving intensive chemotherapy is challenging. Based on the hypothesis that addition of the broad tyrosine kinase inhibitor...
10.
Versluis J, Metzner M, Wang A, Gradowska P, Thomas A, Jakobsen N, et al.
J Clin Oncol
. 2024 Sep;
42(34):4084-4094.
PMID: 39231389
Purpose: AML is a genetically heterogeneous disease, particularly in older patients. In patients older than 60 years, survival rates are variable after the most important curative approach, intensive chemotherapy followed...